Furthermore, there were no significant differences in how patients with different levels of income were treated regarding use of medicines, for example, average number of antibiotic injections (0.87, 0.93 and 0.94 for low-, medium- and high-level income respectively, p = 0.63), and total cost of medicines (LAK 319 645, 324 685, and 370 855 respectively, p = 0.85).
Furthermore, there were no significant differences between trials for any subjective or comfort measure.
Furthermore, there were no significant differences in compressive strengths or beam bending strengths and strains at failure between specimens with or without strip-prone aggregates and with or without amine added.
Furthermore, there were no significant differences between predicted values with measured values of PPO and POD enzymes (p > 0.05); these results indicate the proper performance of the designed models.
Furthermore, there were no significant differences between responders and non-responders in age, age at onset of the mood disorder, duration of index episode, number of previous depressive episodes, number of previous psychiatric hospitalizations, baseline HDRS, or in the type of antidepressive medication (Mann-Whitney U tests, Fisher's exact tests, cf. Table 1).
Furthermore, there were no significant differences in frequency of reactive TCL to hMBP peptide 84-98 in DR15-positive or DR15-negative MS patients.
Furthermore, there were no significant differences regarding the dose of fentanyl and the duration of surgery between the two groups.
Furthermore, there were no significant differences for continuing patients (adalimumab vs. etanercept: p = 0.527; etanercept vs. infliximab: p = 0.565; adalimumab vs. infliximab: p = 0.959 performing the log-rank test).
Furthermore, there were no significant differences in the final tumor volume (Fig. 5c).
Furthermore, there were no significant differences in the level of HMGB1 between WT and RAGE KO silica treated mice (Figure 6C).
Furthermore, there were no significant differences on plasma antioxidant measures between nonsmokers (n = 18) and smokers (n = 13) in the FENNS patients [23].
